Rate Control versus Rhythm Control in Atrial Fibrillation: Lessons Learned from Clinical Trials of Atrial Fibrillation

Progress in Cardiovascular Diseases

Volumn 58, Issue 2, 2015, Pages 168-176

  Waldo, Albert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Atrial fibrillation; Rate control; Rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DIGITALIS; DIGOXIN;

ABLATION THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; HEART RATE AND RHYTHM; HEART RATE CONTROL; HEART RHYTHM CONTROL; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; TREATMENT OUTCOME; ADVERSE EFFECTS; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK FACTOR; SURGERY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84942080833     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.08.006     Document Type: Article

References (44)

1. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
2. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2000, 110:1042-1046.
3. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913-920.
4. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
5. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003, 42:20-29. AFFIRM First Antiarrhythmic Drug Substudy Investigators.
6. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
7. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
8. Waldo A.L., Becker R.C., Tapson V.F., Colgan K.J. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005, 46:1729-1736.
9. Cox J.L., Schuessler R.B., D'Agostino H.J., et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991, 101:569-583.
10. Haïssaguerre M., Jaïs P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659-666.
11. Oral H., Ozaydin M., Tada H., et al. Mechanistic significance of intermittent pulmonary vein tachycardia in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2002, 13:645-650.
12. Moe G.K., Abisdskov J.A. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959, 58:59-70.
13. Lee S., Sahadevan J., Khrestian C.M., Durand D.M., Waldo A.L. High density mapping of atrial fibrillation during vagal nerve stimulation in the canine heart: restudying the Moe hypothesis. J Cardiovasc Electrophysiol 2013, 24:328-335.
14. Gillinov A.M., Gelijns A.C., Parides M.K., et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015, 372:1399-1409.
15. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014, 64:2246-2280.
16. Weerasooriya R., Khairy P., Litalien J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5years of follow-up?. J Am Coll Cardiol 2011, 57:160-166.
17. Cappato R., Calkins H., Chen S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:32-38.
18. Narayan S.M., Krummen D.E., Shivkumar K., Clopton P., Rappel W.J., Miller J.M. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012, 60:628-636.
19. Benharash P., Buch E., Frank P., et al. Quantitative analysis of localized sources identified by focal impulse and rotor modulation mapping in atrial fibrillation. Circ Arrhythm Electrophysiol 2015, 8:554-561.
20. Medi C., Evered L., Silbert B., et al. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol 2013, 62:531-539.
21. Deshmukh A., Patel N.J., Pant S., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93,801 procedures. Circulation 2013, 128:2104-2112.
22. Van Gelder I.C., Wyse D.G., Chandler M.L., et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006, 8:935-942.
23. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010, 362:1363-1373.
24. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010, 31:2369-2429.
25. Wann L.S., Curtis A.B., January C.T., et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:104-123.
26. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014, 64:2305-2307.
27. Olshansky B., Rosenfeld L.E., Warner A.L., et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. Am Coll Cardiol 2004, 43:1201-1208.
28. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533. Digitalis Investigation Group.
29. Rathore S.S., Wang Y., Krumholz H.M. 28 Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
30. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509-1513.
31. Adams K.F., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005, 46:497-504.
32. Halberg P., Lindbäck J., Lindahl B., Stenestrand U., Melhus H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007, 63:959-971.
33. Friberg L., Hammar N., Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart 2010, 96:275-280.
34. Whitbeck M.G., Charnigo R.J., Khairy P., et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013, 34:1481-1498.
35. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013, 34:1489-1497.
36. Turkhia M.P., Santangeli P., Winkelmayer W.C., et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 2014, 64:660-668.
37. Chao T.F., Liu C.J., Chen S.J., et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol 2014, 30:1190-1195.
38. Freeman J.V., Reynolds K., Fang M., et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol 2015, 8:49-58.
39. Washam J.B., Stevens S.R., Lokhnygina Y., et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 2015, 385:2363-2370.
40. Murphy S.A. When "digoxin use" is not the same as "digoxin use": lessons from the AFFIRM trial. Eur Heart J 2013, 34:1465-1467.
41. Reynolds M.R. Outcomes with digoxin in atrial fibrillation: more data, no answers. J Am Coll Cardiol 2014, 64:669-671.
42. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004, 351:2384-2391.
43. Nabar A., Rodriguez L.M., Timmermans C., van den Dool A., Smeets J.L., Wellens H.J. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999, 99:1441-1445.
44. Huang D.T., Monahan K.M., Zimetbaum P., Papageorgiou P., Epstein L.M., Josephson M.E. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998, 9:462-469.